Novasep Expands and Opens Subsidiary in India - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novasep Expands and Opens Subsidiary in India



Novasep, a provider of separation sciences services and fine chemicals, is expanding its presence in India with the opening of Novasep Process Engineering Services, a part of its industrial business unit. The new office will enable Novasep to further serve industries in India producing functional and commodity food and feed ingredients, milk derivatives, and bio-based chemicals. Novasep will continue to sell biopharma chromatography equipment and associated processes in India.

Novasep India will continue to collaborate with the Nilsan Nishotech Systems, which has represented Novasep in India for more than 20 years. Nilsan Nishotech will remain the exclusive agent for Novasep for industrial biotech and biopharma purification processes and systems in India.

Source: Novasep

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here